Zayed Y, et al. - Researchers analyzed the evidence from 12 relevant randomized controlled trials (RCTs) involving 19,322 patients (mean age of 65±8.2 years and 68.2% were male), to compare the safety and efficacy of triple inhaler therapy consisting of an inhaled-glucocorticoid (ICS), long-acting muscarinic-antagonist (LAMA), and long-acting β2-agonist (LABA) to that of dual therapy (ICS-LABA or LAMA-LABA) in the treatment of moderate-to-severe COPD. They identified RCTs comparing between triple and dual inhalers via an electronic database search. According to findings, a reduction of moderate-to-severe COPD exacerbations, improved lung function, and improved quality of life were observed in relation to triple inhaler therapy among patients with moderate-to-severe COPD, compared to dual inhaler therapy. However, an increased pneumonia risk was associated with triple inhaler therapy.